ACG Updates Guidelines for Colorectal Cancer Screening
Recommendation strong for screening average-risk individuals from age 50 to 75 years; recommendation conditional for screening from age 45 years
Gastrohepatic Disorders
Two Peaks in MIS-C Followed COVID-19 Peaks in the US
Lowest proportion of severe manifestations seen in patients aged 0 to 4 years, but 44.3 percent admitted for intensive care
Maralixibat Gets Priority Review for Cholestatic Pruritus in Alagille Syndrome
Maralixibat is an oral apical sodium dependent bile acid transporter (ASBT) inhibitor.
Triple Therapy for Helicobacter pylori Eradication Safe for Adolescents
A team of investigators conducted a prospective, multicenter study to assess the safety of H pylori eradication therapy in adolescent students.
Study Suggests Limited Efficacy of OTC Meds for Chronic Idiopathic Constipation
Results showed that the majority of patients expressed dissatisfaction with the effect of the OTC agent on constipation and CIC-specific abdominal symptoms.
Study Shows Infliximab Superior to Traditional Therapy in Youth With Crohn Disease
More research and follow-up on infliximab is needed to determine the appropriate length of treatment and who will benefit most from treatment.
Rifaximin Prevents Overt Hepatic Encephalopathy After TIPS
For patients with cirrhosis, rifaximin reduces odds of overt HE after transjugular intrahepatic portosystemic shunt
Byfavo Now Available for Induction, Maintenance of Procedural Sedation
Byfavo, a Schedule IV controlled substance, is a rapid-acting, reversible benzodiazepine.
De-Escalation and Discontinuation of Biologics in IBD: What to Consider
Although the definition of remission varies, the goal of IBD treatment is to achieve and sustain remission.
Treatment Success Seen With Antibiotics for Uncomplicated Appendicitis
Seven days of oral antibiotics noninferior to two days of intravenous followed by oral antibiotics
